Abstract: The present invention provides stable pharmaceutical compositions of poorly water soluble pharmaceutical agents and stabilizing agents which function to increase stability of the compositions. The use of stabilizing agents provide extended stability of nanoparticle suspensions and other formulations of poorly water soluble pharmaceutical agents such as docetaxel under certain conditions, for example upon dilution for administration.
Type:
Grant
Filed:
March 11, 2009
Date of Patent:
July 19, 2011
Assignee:
Abraxis Bioscience, LLC
Inventors:
Tapas De, Neil P. Desai, Andrew Yang, Zachary Yim, Patrick Soon-Shiong
Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
Type:
Grant
Filed:
April 12, 2010
Date of Patent:
April 12, 2011
Assignee:
Abraxis BioScience, LLC
Inventors:
Neil P. Desai, Patrick Soon-Shiong, Vuong Trieu
Abstract: In general, in a first aspect, the invention features a method that includes depositing a first material on a surface of an article to form a layer including the first material. The surface of the article includes a plurality of protrusions and the layer including the first material forms a plurality of lenses. Each lens corresponds to a protrusion on the substrate surface.
Abstract: The invention provides for SPARC polypeptides with a mutation corresponding to a deletion of the third glutamine in the mature fault of the human SPARC protein, nucleic acids encoding such polypeptides, antibodies against such polypeptides, and methods of the use of such polypeptides, nucleic acids, and antibodies.
Type:
Application
Filed:
September 10, 2010
Publication date:
January 13, 2011
Applicant:
Abraxis BioScience, LLC
Inventors:
Vuong Trieu, Neil P. Desai, Patrick Soon-Shiong
Abstract: The present invention is related to 10,20-di-O ester derivatives of camptothecin and pharmaceutical formulations thereof. The compounds and pharmaceutical formulations of the present invention possess increased biological life span and bioavailability and reduced toxicity, while maintaining anti-cancer activity.
Type:
Application
Filed:
April 13, 2010
Publication date:
December 2, 2010
Applicant:
Abraxis BioScience, LLC
Inventors:
Patrick Soon-Shiong, Neil P. Desai, Chunlin Tao, Cheng Zhi Yu
Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
Type:
Grant
Filed:
October 26, 2006
Date of Patent:
October 26, 2010
Assignee:
Abraxis Bioscience, LLC
Inventors:
Neil P. Desai, Patrick Soon-Shiong, Vuong Trieu
Abstract: The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.
Type:
Grant
Filed:
July 20, 2007
Date of Patent:
August 24, 2010
Assignee:
Abraxis Bioscience, LLC
Inventors:
Neil P. Desai, Patrick Soon-Shiong, Tapas K. De
Abstract: The present invention provides compositions comprising a poorly water soluble pharmaceutical agent, a carrier protein, and an antimicrobial agent, wherein significant microbial growth is inhibited in the composition. The amount of the antimicrobial agent in the composition may be below the level that induces a toxicological effect or at a level where a potential side effect can be controlled or tolerated. Also provided are compositions comprising a poorly water soluble pharmaceutical agent, a carrier protein, a sugar, and optionally an antimicrobial agent. Methods of using the compositions are also provided.
Type:
Grant
Filed:
August 30, 2006
Date of Patent:
August 10, 2010
Assignee:
Abraxis Bioscience, LLC
Inventors:
Neil P. Desai, Raj Selvaraj, Andrew Yang, Patrick Soon-Shiong
Abstract: The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.
Abstract: The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents (such as an anti-VEGF antibody), or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.
Abstract: The present invention is related to 10,20-di-O ester derivatives of camptothecin and pharmaceutical formulations thereof. The compounds and pharmaceutical formulations of the present invention possess increased biological life span and bioavailability and reduced toxicity, while maintaining anti-cancer activity.
Type:
Grant
Filed:
December 23, 2004
Date of Patent:
April 20, 2010
Assignee:
Abraxis BioScience, LLC
Inventors:
Patrick Soon-Shiong, Neil P. Desai, Chunlin Tao, Cheng Zhi Yu
Abstract: The invention provides 2 aryl substituted derivatives of melatonin. The invention further provides pharmaceutical compositions comprising such derivatives, methods for preparing such derivatives, and methods of using such derivatives to induce general anesthesia, sedation, and/or hypnotic or sleep effects in a patient, and to treat conditions affected by melatonin activity in a patient.
Type:
Grant
Filed:
December 23, 2004
Date of Patent:
March 9, 2010
Assignee:
Abraxis BioScience, LLC
Inventors:
Chunlin Tao, Cheng-Zhi Yu, Neil P. Desai, Vuong Trieu
Abstract: This invention provides methods and compositions for screening of microRNA capable of modulating gene expression in the apoptotic pathway in the presence of HSP90 inhibitor. The use of miRNA for enhancing the activity of therapeutic agents not limited to HSP90 inhibitor is also disclosed. The diagnostic use of miRNA for predicting response to therapy not limited to therapeutic agents is also disclosed.
Abstract: miRNAs that regulate human SPARC and methods of use thereof are described. Suitable nucleic acids for use in the methods and compositions described herein include, but are not limited to, pri-miRNA, pre-miRNA, ds miRNA, mature miRNA or fragments of variants thereof that retain the biological activity of the mature miRNA and DNA encoding a pri-miRNA, pre-miRNA, mature miRNA, fragments or variants thereof, or regulatory elements of the miRNA.